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Abstract 
Background: Buprenorphine maintenance for opioid dependence remains of limited availability among under-
served populations, despite increases in US opioid misuse and overdose deaths. Low threshold primary care treat-
ment models including the use of unobserved, “home,” buprenorphine induction may simplify initiation of care and 
improve access. Unobserved induction and long-term treatment outcomes have not been reported recently among 
large, naturalistic cohorts treated in low threshold safety net primary care settings.
Methods: This prospective clinical registry cohort design estimated rates of induction-related adverse events, treat-
ment retention, and urine opioid results for opioid dependent adults offered buprenorphine maintenance in a New 
York City public hospital primary care office-based practice from 2006 to 2013. This clinic relied on typical ambula-
tory care individual provider-patient visits, prescribed unobserved induction exclusively, saw patients no more than 
weekly, and did not require additional psychosocial treatment. Unobserved induction consisted of an in-person 
screening and diagnostic visit followed by a 1-week buprenorphine written prescription, with pamphlet, and tele-
phone support. Primary outcomes analyzed were rates of induction-related adverse events (AE), week 1 drop-out, and 
long-term treatment retention. Factors associated with treatment retention were examined using a Cox proportional 
hazard model among inductions and all patients. Secondary outcomes included overall clinic retention, buprenor-
phine dosages, and urine sample results.
Results: Of the 485 total patients in our registry, 306 were inducted, and 179 were transfers already on buprenor-
phine. Post-induction (n = 306), week 1 drop-out was 17%. Rates of any induction-related AE were 12%; serious 
adverse events, 0%; precipitated withdrawal, 3%; prolonged withdrawal, 4%. Treatment retention was a median 
38 weeks (range 0–320) for inductions, compared to 110 (0–354) weeks for transfers and 57 for the entire clinic popu-
lation. Older age, later years of first clinic visit (vs. 2006–2007), and baseline heroin abstinence were associated with 
increased treatment retention overall.
Conclusions: Unobserved “home” buprenorphine induction in a public sector primary care setting appeared a 
feasible and safe clinical practice. Post-induction treatment retention of a median 38 weeks was in line with previous 
naturalistic studies of real-world office-based opioid treatment. Low threshold treatment protocols, as compared to 
national guidelines, may compliment recently increased prescriber patient limits and expand access to buprenor-
phine among public sector opioid use disorder patients.
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Background
Buprenorphine, approved for office-based treatment of 
opioid use disorders (opioid dependence) by waivered 
prescribers, has become the cornerstone of opioid treat-
ment in the US [1–3]. Consistent with a chronic disease 
model, long-term buprenorphine maintenance has been 
shown superior to short-term tapers or time-limited 
treatment windows [4, 5]. However, too few patients 
overall access buprenorphine, particularly in rural areas 
and among the Medicaid-insured and underserved [6–8]. 
A 2013 New York City survey of buprenorphine-waivered 
physicians estimated that only 10% accepted Medicaid, 
meaning higher prescriber patient ‘caps’ and Medicaid 
expansion theoretically only impact a small proportion 
of the total providers who serve public sector patients 
[9]. We surveyed N =  72 NYC public sector buprenor-
phine providers in 2016 regarding barriers to prescrib-
ing; time and resource constraints were among the most 
heavily agreed to barriers to buprenorphine practice [10]. 
Per multiple provider survey studies conducted since 
buprenorphine’s 2002 US approval, limited clinician time, 
office space, support staff, reimbursement, and induction 
logistics are barriers to prescribing [11–15].
These familiar buprenorphine practice barriers 
reflect ‘high threshold’ practice standards, as defined 
by somewhat dated but still current Substance Abuse 
and Mental Health Service Administration (SAMHSA) 
office-based buprenorphine guidelines, the Treatment 
Improvement Protocol (TIP) 40, Clinical Guidelines for 
the Use of Buprenorphine in the Treatment of Opioid 
Addiction [1, 2]. TIP40 remains the basis of mandatory 
buprenorphine-waiver training courses. These guide-
lines, as well as buprenorphine product labels, endorse 
only in-office, observed buprenorphine induction dur-
ing a potentially prolonged office visit, recommend 
daily or frequent follow-up immediately post-induc-
tion, and heavily emphasize ancillary psychosocial 
counseling concurrent with pharmacotherapy medi-
cal management (Table  1) [16]. TIP40 has presumably 
heavily influenced payer policies, such as buprenor-
phine prior authorization (PA) criteria. One current 
New York State payer’s PA, for example, requires that 
a buprenorphine patient be enrolled in “substance 
abuse rehabilitation services,” in addition to an indi-
vidual prescriber’s practice [17]. More recent consen-
sus guidelines from the American Society of Addiction 
Medicine (2015) have evolved and arguably liberalized 
some of the original TIP40 recommendations regard-
ing observed versus unobserved induction, the timing 
of immediate post-induction observation, and recom-
mendations for additional psychosocial counseling [3]. 
The 2015 ASAM guidelines, however, preserve many of 
the relatively intensive office-based protocols requir-
ing more space, time, and effort than may be needed 
for safe and effective treatment, including routine use 
of observed induction, reserving unobserved induction 
only for experienced providers or patients, and a blan-
ket endorsement of additional psychosocial counseling, 
particularly for new buprenorphine patients.
Since 2002, many buprenorphine providers in public 
sector, general care, HIV, and harm reduction clinical set-
tings have customized leaner, lower threshold buprenor-
phine practices, which seek to provide quality care while 
working in resource-constrained settings [18–24]. Our 
own office-based primary care clinic in a New York City 
public hospital is characterized by the following: pre-
dominantly Medicaid or uninsured patients, universal 
unobserved buprenorphine induction following an initial 
new patient visit and a diagnosis of opioid dependence, 
weekly then less frequent follow-up, and a general recom-
mendation but no requirement or mandate for additional 
psychosocial treatment, which has otherwise not been 
available in our clinic [25]. During unobserved or “home” 
buprenorphine induction, the patient is diagnosed with 
opioid dependence during their initial office visit, offered 
a buprenorphine prescription, provided with instructions 
to self-administer initial induction and maintenance 
doses after leaving clinic and when experiencing opi-
oid withdrawal symptoms, and instructed to return at a 
later time [26]. Subsequent follow-up visits occur at our 
clinic weekly, then bi-weekly, then monthly or less fre-
quently among stable patients. While we encourage all of 
our patients to access additional community treatment, 
counseling and 12-step resources, these are not man-
dates; psychosocial support is primarily delivered during 
the provider-patient medical management visit, which is 
structured as a standard ambulatory care follow-up visit.
We have offered this version of low threshold office-
based buprenorphine treatment since 2006 in a New 
York City Public Hospital adult primary care clinic, but 
have not examined overall or long-term (12+ months) 
retention, or factors associated with time in treatment, 
including unobserved induction outcomes. Long-term 
retention in office-based buprenorphine treatment has 
not been widely studied; other sites have reported around 
50–60% retention at 12-months [18, 24], and 38% at 
24-months among patients initially successful in treat-
ment [27]. This prospective cohort study analyzed a con-
secutive registry of buprenorphine patients treated in our 
practice over a 7-year period, 2006–2013, and tracked 
patient characteristics, induction outcomes, and treat-
ment retention.
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Methods
The clinical site, populations, and clinic and assessment 
procedures for initial and follow-up visits, unobserved 
buprenorphine induction, and data collection have been 
previously described and are briefly summarized here 
[25].
Site
Since August 2006, the Bellevue Hospital Adult Pri-
mary Care Center, a large urban-public hospital, has 
offered office-based buprenorphine treatment for opioid 
dependent adults. A physician team comprised of 5–6 
Internal Medicine physicians, of whom 3 were certified 
in Addiction Medicine, co-managed a buprenorphine 
patient panel during two weekly half-day sessions. Phy-
sicians were generally available for off-schedule in-clinic 
consultations for any urgent matters during regular clinic 
hours and by phone at all times.
Population
The clinic offered office-based induction and mainte-
nance treatment to opioid dependent adults age 18 years 
or older. Referral sources included detoxification units, 
chemical dependency outpatient programs, the criminal 
justice system, other primary care providers, and patient 
word-of-mouth.
Initial induction visit
Buprenorphine treatment was offered following a clini-
cal diagnosis of opioid dependence per Diagnostic and 
Statistics Manual-IV and product labels, and a co-signed 
physician-patient office-based buprenorphine treatment 
plan. Physicians assessed medical, psychiatric, and sub-
stance use diagnoses during a 30–45-minute new patient 
appointment. Urine toxicology assays were mandatory. 
Hepatitis C and HIV screening was encouraged through-
out treatment but not mandated at baseline; similarly, 
liver serologies were obtained when indicated and not 
mandated at baseline.
A bilingual pictogram-based pamphlet instructed 
patients step by step on unobserved induction using a 
“teach-back” method. Initial buprenorphine prescrip-
tions for both induction and transfer-in patients (patients 
already on a stable buprenorphine dose but new to our 
clinic) were written for seven days, usually for fourteen 
8-mg/2-mg tablets, with follow-up in one week. This 
induction pictogram is available as an on-line resource 
as part of a prior manuscript [25]. Induction and main-
tenance was undertaken exclusively with prescription of 
the combination buprenorphine-naloxone products; the 
exception being pregnant patients, who were prescribed 
buprenorphine monotherapy (Subutex).
Follow-up visits
Standard 20-min ambulatory visits occurred every 
1–4  weeks during the first few months of treatment. 
Patients stable on maintenance doses were seen at 
4–16  week intervals thereafter. Shorter visit intervals 
were scheduled if illicit opioid, other drug misuse or 
other problematic behaviors or safety concerns persisted. 
A Medical Management treatment platform counseled 
around treatment goals including illicit opioid abstinence 
and improved functional status, medication side effects 
and dosing, encouragement of ancillary drug treatment, 
counseling or 12-step engagement, and addressed pri-
mary medical care and health maintenance issues. Main-
tenance dosing ranged from 2–32  mg/day until around 
2009–2010, when New York State Medicaid dispens-
ing limits and evolving clinical experience consolidated 
around a 2–24  mg/day maintenance dose range. Urine 
toxicology was obtained at each visit. Psychiatrically 
co-morbid patients were referred to on-site psychiat-
ric services. If patients were repeatedly unable to keep 
scheduled appointments, unusually disruptive or threat-
ening, highly likely to be diverting buprenorphine, or had 
continued uncontrolled opioid or other drug use that 
was deemed unsafe for continued controlled substance 
prescribing and office-based treatment, the buprenor-
phine dose would be tapered and the patient referred to 
a higher level of care, including a within-hospital opioid 
treatment program.
Data collection
All individual patients receiving a buprenorphine pre-
scription from August 2006 through June 31, 2013 were 
included in a clinical registry. An initial clinical assess-
ment documented demographic characteristics, lifetime 
substance use, and addiction treatment histories. Follow-
up assessments documented treatment outcomes (i.e., 
induction adverse events, opioid and other drug misuse 
by self-report and urine toxicology). This data, in addi-
tion to visit attendance and prescription records, were 
periodically extracted from the electronic medical record 
to compile a registry dataset. Retrospective chart review 
was conducted in cases of incomplete or missing data. 
The dataset was de-identified for analysis and managed 
using Research Electronic Data Capture (REDCap). The 
New York University School of Medicine Institutional 
Review Board approved this registry protocol.
Outcomes and analysis
The subset of patients presenting for buprenorphine 
induction (versus those transferring their care, already 
on buprenorphine maintenance by self-report) was iden-
tified. Baseline characteristics were summarized using 
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descriptive statistics. Primary outcomes of interest were 
follow-up rates at 1-week post-induction and rates of 
adverse events (AEs) and serious adverse events (SAEs). 
AEs were classified into four categories: 1) precipitated 
opioid withdrawal, defined as any sudden onset or wors-
ening of opioid withdrawal symptoms following the initial 
dose of buprenorphine, 2) protracted opioid withdrawal, 
defined as opioid withdrawal symptoms that began 
before induction and persisted until or past day 2 of 
treatment, 3) SAEs, defined as death, a life-threatening or 
other event necessitating emergency medical treatment, 
hospitalization, or persistent or significant disability or 
incapacity, and 4) other adverse events. Bivariate logistic 
regression estimated associations of prior buprenorphine 
experience and methadone-to-buprenorphine, two base-
line variables of interest, with any induction-related AE.
Treatment retention was analyzed as a continuous vari-
able (weeks) consisting of the time between the initial and 
last week of the last active buprenorphine maintenance 
or taper prescription. Kaplan-Meyer survival curves dis-
played overall retention among the total clinic cohort, 
inductions, and transfers. Cox proportional hazard mod-
els, among the total clinic cohort and among inductions, 
examined associations with retention. We excluded from 
this survival analysis n =  8 patients with mean gaps in 
treatment of > 18 weeks, indicating sporadic and in effect 
multiple treatment episodes rather than a continuous 
single treatment episode. We described several outcomes 
across the total clinic cohort, including buprenorphine 
maintenance dose levels (median, range) and rates of 
positive urine toxicology samples, which were summa-
rized as overall group means across time in treatment.
Results
From August 2006 through June 2013, 485 patients were 
prescribed buprenorphine, 306 of these were inducted, 
and 179 transfers were already on buprenorphine from 
a previous provider (Table  2). Induction patients were 
primarily male, Medicaid-insured, and most (68%) had 
previous experience taking buprenorphine (either licit or 
illicit). Nearly all (92%) were primarily using and depend-
ent on heroin (vs. prescription opioids), used intranasally, 
and were current tobacco smokers (82%). Compared to 
transfers, induction patients included a higher rate of 
homelessness (defined as shelter or street homeless) and 
were more likely African American (vs. White).
Unobserved induction outcomes included week 1 
retention of 83% (Table  3). There were a total of 38 AE 
reported (12% of 306 total inductions; 15% of 254 retained 
at week 1). Eleven (3% of 306) patients reported precipi-
tated withdrawal; 14 (5% of 306) prolonged withdrawal. 
No SAEs were observed or reported. Prior buprenor-
phine experience and methadone-to-buprenorphine 
inductions were not associated with induction AE (data 
not shown).
Treatment retention was a median of 38 weeks (range 
0–320  weeks) among induction patients (n  =  302); 
110  weeks (0–353  weeks) among transfers (n  =  175), 
and 57 weeks for all patients (n = 477) (Fig. 1). Among 
inductions, 25% dropped out by week 5, 50% by week 
38, and 75% by week 144, or around 3 years following an 
initial visit. Factors associated with shorter time to drop-
out in adjusted Cox proportional hazard models were, 
among the entire clinic population: age, some later years 
of first clinic visit versus a combined 2006–2007 ‘refer-
ence year’, induction (vs. transfer), and active heroin use 
(Table 4). Among inductions only, no factor was signifi-
cantly associated with time to drop-out in an adjusted 
model, including prior buprenorphine experience, or 
induction-related adverse events. Reporting other outpa-
tient counseling of 12-step involvement at baseline was 
not associated with time to drop-out in all patients or 
inductions.
The median dose of buprenorphine, calculated from 
the last prescribed maintenance dose for each patient, 
was 16 mg (range 1–32 mg; mean, 18 mg). Overall, there 
was a mean opiate positive urine toxicology rate of 40% 
across all treatment visits. Rates were 24% for cocaine 
and 17% for benzodiazepines. Opiate positive urine rates 
declined with longer treatment retention: among patients 
who were in treatment <12 weeks, the rate of opiate posi-
tive urines was 60%; >24 weeks, 30%; and >52 weeks, 27% 
(p < 0.001).
Discussion
This naturalistic registry study examined up to 7 years of 
treatment retention among underserved opioid depend-
ent adults receiving buprenorphine maintenance in a 
low threshold, public hospital, office-based primary care 
setting. This included 306 new patients exclusively initi-
ated onto buprenorphine by unobserved induction. A 
typical new induction patient during 2006–2013 was a 
Medicaid-insured, heroin-dependent adult male who 
uneventfully began buprenorphine treatment, remained 
in maintenance for about 9 months, and saw diminishing 
rates of opioid misuse as time in treatment lengthened. 
Long-term retention among new induction patients 
was comparable to previous studies from other cent-
ers, with over half retained in treatment at 24 weeks and 
20% retained for greater than 3 years [18, 27]. Including 
transfers already established on buprenorphine at treat-
ment episode entry, the median time in treatment for any 
new patient was 110 weeks, or over 2 years of follow-up 
among half of our patients.
These results compare favorably to usual retention 
and adherence rates for patients with other chronic 
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conditions, such as hypertension, diabetes, or HIV; 
prevalent conditions which are in fact quite difficult to 
adequately control and regularly monitor in a majority 
of patients within a typical public sector primary care 
practice across extended periods of time [28–30]. A small 
number of our transfer patients were in early buprenor-
phine clinical trials, and have maintained on buprenor-
phine since before FDA approval in 2002. Long-term, 
presumably indefinite, office-based buprenorphine main-
tenance appears an important and sustainable treatment 
outcome for a substantial proportion of patients. In a 
recent long-term follow-up survey of former partici-
pants in a prescription opioid addiction buprenorphine 
treatment trial, 37% of available participants surveyed at 
Month 42 post-randomization reported continued opi-
oid agonist maintenance [31]. In our sample as in others, 
Table 2 Baseline patient characteristics
* Indicates baseline demographics that are statistically different (<0.05) between induction patients and patients transferring care, using Fisher’s exact test or Chi 
square test of independence
a Inductions refer to patients offered a new buprenorphine induction prescription. Transfers were existing buprenorphine patients transferring care to our practice 
and induced elsewhere onto buprenorphine
b  Missing data: all patients (n = 138); inductions (n = 85); transfers (n = 53)
c Missing data: all patients (n = 280), inductions (n = 19), transfers (n = 7)
d Missing data: all patients (n = 18), inductions (9), transfers (n = 9)










Mal 402 (83) 256 (84) 146 (82)
Age, average (range) 47 (23–73) 47 (24–71) 47 (24–73)
Race and ethnicityb
 Black 140 (29) 107 (35)* 33 (18)
 Hispanic 60 (12) 38 (12) 22 (12)
 White 147 (30) 76 (25)* 71 (40)
Insurance statusc
 Medicaid 294 (61) 193 (64) 101 (56)
 Commercial 39 (8) 15 (5)* 24 (13)
 Medicare 11 (2.5) 6 (2) 5 (3)
 Uninsured/self pay 113 (23) 71 (22) 42 (24)
Unemployed
 Homeless (shelter or street)d 80 (16) 64 (21)* 16 (9)
 History of Incarceratione 338 (70) 227 (74)* 111 (62)
 Hepatitis C positive, self-report 152 (31) 95 (30) 57 (40)
 HIV positive, self-report 47 (10) 32 (10) 15 (10)
Opioid use
 Heroin use, last 7 days 252 (52) 220 (72)* 32 (18)
 Heroin use, lifetime 444 (92) 289 (94)* 155 (87)
 Prescription opioid misuse, last 7 days 105 (22) 88 (29)* 17 (10)
 Prescription opioid Misuse, lifetime 274 (56) 174 (57) 100 (56)
 IV drug use, last 7 days 104 (22) 88 (29)* 16 (9)
 Buprenorphine, previous illicit or licit use 368 (76) 199 (65)* 179 (100)
 Methadone maintenance, previous 295 (61) 191 (62) 104 (63)
 Methadone maintenance, current 26 (7) 26 (8)* 0 (0)
Other drug use
 Cocaine use, last 7 days 102 (21) 76 (25)* 26 (15)
 Benzodiazepine use, last 7 days 57 (12) 36 (12) 21 (12)
 Cannabis use, last 7 days 83 (17) 53 (17) 30 (18)
 Heavy drinking (>5 drinks per occasion), last 12 months 125 (26) 85 (28) 40 (24)
 Smoking, current 391 (81) 252 (82) 139 (78)
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longer time in treatment corresponded to higher rates of 
heroin and other opioid abstinence.
Unobserved induction outcomes reported here add to a 
now sizable body of literature demonstrating overall fea-
sibility/acceptability and low rates of complications asso-
ciated with unobserved buprenorphine induction [21, 26, 
32, 33]. There were no SAEs reported from the patients 
for whom we had post-induction follow up and low rates 
of precipitated withdrawal. Precipitated withdrawal 
appears to occur in about 5–10% of inductions, regard-
less of unobserved or observed induction approaches 
[34–36]. Among week 1 dropouts, there were likely addi-
tional cases of precipitated withdrawal or SAEs. Pre-
viously, however, we have shown that buprenorphine 
patients dropping out at week 1 but providing follow-up 
by phone were very likely to have had insurance or self-
pay issues which prevented filling the initial buprenor-
phine-naloxone prescription and any induction [25]. 
Rates of week 1 drop-out range from 6 to 28% in the liter-
ature, and appear to occur regardless of observed versus 
unobserved approaches [37–39].
Among inductions, no single baseline factor predicted 
longer retention (time-in-treatment). Analyzing the 
entire cohort of induction and transfer patients, young, 
active heroin users had the shortest retention. Several 
factors did not associate with differential retention as 
expected, including previous buprenorphine experi-
ence and induction-related adverse events [40]. Patient 
self-report of previous experience with buprenorphine 
became increasingly common: 84% from 2008 to 2013 
versus 37% during 2006–2007. As prior buprenorphine 
experience among new patients grew, initial associations 
with retention likely diminished. This same trend towards 
widespread experience with buprenorphine among out-
of-treatment opioid dependent individuals also likely 
explained mush about the relative ease and safety of 
unobserved induction over time. Patients increasingly 
had already taken, used, and experienced buprenor-
phine safely and effectively on their own. Active heroin 
use, versus non-heroin opioid use or transferring patients 
already relatively stable on buprenorphine, and younger 
age, are both familiar risk factors for worse opioid treat-
ment outcomes, including treatment drop-out [41–43]. 
Uninsured versus active health insurance did not affect 
retention, likely due to the New York City Health + Hos-
pital Corporation’s outpatient pharmacy policies, which 
supported buprenorphine maintenance for all patients 
regardless of their ability to pay. Pharmacy benefits and 
health insurance coverage are crucial components of ade-
quate chronic disease management.
Higher threshold, guideline-based new buprenorphine 
patient protocols, consisting of observed induction, as 
much as daily initial in-clinic follow-up post-induction, 
and requirements or strong recommendations for addi-
tional psychosocial counseling, are arguably idealized 
versions of traditional opioid treatment programs or 
intensive outpatient models of care, and may limit overall 
prescribing. Further, these guideline-based recommen-
dations are not clearly evidence-based, as with unob-
served versus observed induction. While the field lacks 
a large, definitive randomized trial of observed versus 
unobserved induction, there is to date no evidence from 
any clinical trials or observational study supporting any 
particular buprenorphine induction approach as supe-
rior or inferior in terms of safety, retention, or opioid 
abstinence [26, 32, 33]. The weight of the evidence from 
observational, non-randomized trials points to the two 
induction approaches as being essentially equivalent and 
the outcomes the same regardless of patient character-
istics or provider experience. A recent large emergency 
department buprenorphine initiation randomized trial, 
for instance, adopted unobserved induction in a majority 
(57%, 65 of 114) of participants randomized to buprenor-
phine safely and by necessity; it was not practical to 
Table 3 Unobserved induction outcomes
a Other reported AEs included likely induction-related complaints not 
consistent with precipitated or prolonged withdrawal syndromes
Induction outcome n (%)
Unobserved induction cases 305 (100)
Lost to follow-up at week 1 52 (17)
≥1 induction-related adverse event (AE) 38 (13)
 Precipitated withdrawal 10 (3)
 Prolonged withdrawal 13 (4)
 Serious adverse event (SAE) 0 (0)




















Fig. 1 Kaplan Meyer survival curves: retention in treatment: all 
patients (N = 477), inductions (n = 302), and transfers (n = 175). 
Excludes n = 8 participants with >18 week gaps between visits: 4 
inductions, 4 transfers
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hold and observe many ED patients newly diagnosed 
with an opioid disorder and appropriate for buprenor-
phine induction long enough to complete an observed 
induction in the ED [44]. Regarding additional psycho-
social counseling for new or established buprenorphine 
patients, which is not available in a typical primary care 
practice, the evidence to date is explicitly clear that addi-
tional counseling plus office-based buprenorphine is inef-
fective at improving retention, taper success/failure, or 
rates of illicit opioid use compared to office-based medi-
cal management alone [37, 45–48]. Baseline involvement 
in other outpatient behavioral counseling or 12-step did 
not correlate with longer retention in this study. A recent 
related analysis of pre-treatment 12-step involvement 
and in-treatment 12-step mandates for buprenorphine 
patients showed some associations with longer retention 
and pre-treatment involvement, but no association with 
retention and in-treatment 12-step mandates [49].
Lower versus higher threshold office-based practice, 
or unobserved versus observed induction, essentially 
appear to be a matter of clinician and patient prefer-
ences and available clinical resources. Either induction 
approach seems to allow for new patients to induct onto 
buprenorphine safely and effectively. In-office observed 
induction is by definition more logistically, time- and 
resource-intensive, and is repeatedly cited as a barrier 
to buprenorphine prescribing. While the most recent 
ASAM guidelines endorse unobserved induction among 
experienced providers and patients, unobserved induc-
tion should arguably be the default induction protocol 
for most patients and providers, if the overall goal is to 
rapidly and substantially increase the number of active 
office-based providers and patients. This has been the 
case in France, which implemented general practitioner-
prescribed buprenorphine maintenance as a public 
health approach to heroin addiction and overdose deaths, 
without guidelines requiring in-office observed induc-
tion or mandating psychosocial counseling involvement 
[50]. The US buprenorphine X-waiver training and regis-
tration requirements, increasing but still limited patient 
caps, and these historically conservative treatment 
guidelines favoring higher-threshold models of care; 
all of these arguably limit access to buprenorphine. US 
buprenorphine restrictions remain in stark contrast to 
the routine use of any other schedule II or III controlled 
substance, including opioid analgesics and benzodiaz-
epines. Reducing barriers to buprenorphine access is now 
a national public health priority. Low threshold practice 
models have an obvious and important role to play in a 
successful expansion.
Table 4 Factors associated with drop-out (fewer weeks in treatment), Cox proportional hazard models
Factors not shown and not significantly associated with retention among all patients or inductions: gender, ethnicity, homelessness, uninsured, active benzodiazepine 
or cannabis use
a Hazard model adjusted for age, year of first visit, inducted, active baseline heroin and cocaine use. All transfer patients had prior buprenorphine experience; adding 
this term to the model reduces the significance of induction and vice versa
b Hazard model adjusted for age, unemployment, year of first visit, prior buprenorphine experience, active baseline heroin and cocaine use
Baseline or induction-related char-
acteristic
All patients, n = 477 Inductions, n = 302
Hazard ratio 95% CI Adjusteda HR 95% CI Hazard ratio 95% CI Adjustedb HR 95% CI
Age (increasing by year) 0.99 0.97–1.00 0.98 0.97–1.00 0.99 0.97–1.00 0.99 0.97–1.00
Unemployed 0.87 0.68–1.10 – – 0.72 0.54–0.95 0.74 0.54–1.01
Year of First Visit (ref. 2007)
 2008 0.66 0.45–0.96 0.81 0.54–1.20 1.02 0.63–1.66 1.10 0.62–1.96
 2009 0.65 0.48–0.88 0.67 0.49–0.91 0.78 0.55–1.11 0.94 0.64–1.38
 2010 0.75 0.55–1.04 0.75 0.54–1.04 0.72 0.48–1.07 0.88 0.57–1.35
 2011 0.67 0.47–0.97 0.70 0.49–1.01 0.83 0.54–1.28 1.00 0.63–1.58
 2012 0.62 0.36–1.06 0.61 0.35–1.05 0.61 0.31–1.22 0.67 0.33–1.36
 2013 0.64 0.29–1.38 0.62 0.29–1.34 0.60 0.24–1.50 0.70 0.28–1.78
Inducted 1.71 1.36–2.16 1.46 1.10–1.93 – – – –
Prior buprenorphine 1.29 0.49–0.82 – – 0.79 0.60–1.04 0.79 0.58–1.06
Heroin use, active 1.59 1.27–1.99 1.25 0.96–1.64 1.20 0.89–1.61 1.27 0.93–1.75
Cocaine use, active 1.32 1.03–1.71 1.18 0.90–1.54 1.22 0.91–1.63 1.15 0.83–1.59
Outpatient counseling, active 0.97 0.72–1.31 – – 0.81 0.54–1.21 – –
12-step attendance, active 1.01 0.79–1.29 – – 1.02 0.77–1.37 – –
Any induction-related AE – – – – 1.24 0.84–1.81 – –
Methadone-to-buprenorphine induc-
tion
– – – – 1.02 0.64–1.64 – –
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Limitations
This study has important limitations. The clinical pro-
tocols described were not contrasted with compari-
son conditions or interventions. Our clinic only offered 
unobserved inductions, weekly or less frequent follow-up 
with physician prescribers, and mandated or offered no 
in-clinic ancillary counseling. The registry cohort design 
lacked any observed induction or other more intensive 
control condition. Results do not demonstrate that unob-
served induction is equally safe, effective, equivalent, or 
non-inferior versus unobserved induction. Outcomes 
were derived from clinical assessments and the electronic 
medical record, including patient-reported induction 
adverse events and retention (time to drop-out). Reten-
tion estimates included periods of missed visits and 
delayed prescription refills, which are common in many 
patients. While we restricted the survival analysis to 
patients with 18 weeks or less between any two visits, we 
did not otherwise control for shorter gaps in care. This 
likely underestimated the extent to which adherence to 
daily buprenorphine maintenance can be intermittent 
and episodic in many patients, as possibly evidenced 
by the 27% positive opioid urine rate among all patients 
retained in treatment for one year or longer.
Conclusion
This longitudinal analysis of a large public hospital pri-
mary care office-based buprenorphine patient registry 
confirmed that unobserved buprenorphine induction 
appears a safe, acceptable, feasible, and logistically simple 
approach to buprenorphine induction. This is in contrast 
to current US treatment guidelines and buprenorphine 
product labeling, all of which specify observed induction. 
Overall, a low threshold office-based treatment paradigm 
relying on weekly or less frequent follow-up and not 
requiring additional psychosocial counseling was com-
patible with robust long-term treatment retention among 
a primarily heroin dependent, underserved patient popu-
lation. Continued efforts to expand access to low-bar-
rier buprenorphine maintenance are warranted. Future 
updates to US treatment guidelines should consider 
unobserved buprenorphine induction as an accepted 
standard of care.
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